Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Change in Account Payables (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Change in Account Payables for 7 consecutive years, with -$2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 168.03% to -$2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.4 million, a 284.16% decrease, with the full-year FY2025 number at $1.7 million, up 19.5% from a year prior.
  • Change in Account Payables was -$2.9 million for Q4 2025 at Outlook Therapeutics, down from $30255.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.2 million in Q4 2024 to a low of -$4.6 million in Q1 2025.